{"id":55772,"date":"2023-04-13T12:05:41","date_gmt":"2023-04-13T10:05:41","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/"},"modified":"2023-04-13T12:05:41","modified_gmt":"2023-04-13T10:05:41","slug":"turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/","title":{"rendered":"Turnstone Biologics to Present Preclinical Data for Selected TIL Therapy at the 2023 American Association for Cancer Research (AACR) Annual Meeting"},"content":{"rendered":"
\n

\nPresentations demonstrate therapeutic potential of Turnstone\u2019s selected tumor-infiltrating lymphocyte therapy in a broad range of solid tumors and support ongoing clinical efforts for its lead program, TIDAL-01<\/i><\/p>\n

<\/a><\/p>\n

SAN DIEGO–(BUSINESS WIRE)–#AACR2023<\/a>–Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation immunotherapies to treat solid tumors, today announced that two abstracts have been accepted for poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in Orlando, Florida, April 14-19, 2023. The presentations include preclinical data for TIDAL-01, Turnstone\u2019s lead tumor-infiltrating lymphocyte therapy candidate based on the selection of tumor-reactive T cells (Selected TILs), which is currently being evaluated in two Phase 1b trials, as well as data showcasing an additional strategy for tumor-reactive T cell selection.<\/p>\n

\n\u201cWe look forward to sharing preclinical data at the AACR Annual Meeting which continue to validate the exciting potential of our next-generation Selected TILs across a wide range of solid tumors<\/i>,\u201d said Stewart Abbot, Ph.D., Chief Scientific Officer, Turnstone Biologics. \u201cThese results build upon evidence from our previously published data and further demonstrate the successful expansion and significant enrichment of our TILs using innovative selection strategies for identifying tumor-reactive T cells, and support clinical advancement of TIDAL-01 and our pipeline programs.\u201d<\/i><\/p>\n

\nThe work reflects Turnstone\u2019s on-going collaboration with the University of Montreal Hospital Research Centre [Centre de recherche du Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, (CRCHUM)].<\/p>\n

\nFull abstracts are available through the AACR conference website, and details of the poster presentations are as follows:<\/p>\n

\nTitle<\/b>: TIDAL-01: A selected TIL process that enriches for neoantigen-reactive TIL in solid tumors
\n
Session Category<\/b>: Immunology
\n
Session Title<\/b>: Adoptive Cell and Natural Killer Cell Therapy
\n
Session Date and Time<\/b>: April 18, 2023, 9:00 a.m. \u2013 12:30 p.m.
\n
Location: <\/b>Orange County Convention Center, Poster Section 22
\n
Poster Board Number<\/b>: 1
\n
Published Abstract Number<\/b>: 4049<\/p>\n

\nTitle<\/b>: Direct selection of PD1+ CD39+ tumor-infiltrating lymphocytes (TIL) from tumor dissociates enrich for functional tumor-reactive cells
\n
Session Category<\/b>: Immunology
\n
Session Title<\/b>: Adoptive Cell and Natural Killer Cell Therapy
\n
Session Date and Time<\/b>: April 18, 2023, 9:00 a.m. \u2013 12:30 p.m.
\n
Location: <\/b>Orange County Convention Center, Poster Section 22
\n
Poster Board Number<\/b>: 4
\n
Published Abstract Number<\/b>: 4052<\/p>\n

\nAbout Turnstone Biologics<\/b><\/p>\n

\nTurnstone Biologics is a clinical-stage biotechnology company developing new medicines to treat solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (TIL) therapy. Building on the clinical validation in the field, Turnstone\u2019s innovative TIL therapy is based on identification, selection, and expansion of the most potent tumor-reactive T cells, known as Selected TILs, which have the potential to extend therapeutic benefit and curative outcomes to a broader set of solid tumor indications, beyond where current first-generation TILs have proven effective. The Company\u2019s leading therapy, TIDAL-01, is currently being evaluated in two Phase 1b studies in patients with melanoma, breast cancer, and colorectal cancer. Turnstone has also forged strong partnerships with leading cell therapy researchers and international cancer medical centers, including a landmark strategic alliance with the Moffitt Cancer Center covering research, manufacturing, and clinical development, and a CRADA with the National Cancer Institute to explore unique combinations of Selected TILs with Turnstone\u2019s proprietary viral immunotherapies.<\/p>\n

\nFor more information, please visit www.turnstonebio.com<\/a>, and follow us on LinkedIn<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nAhmed Aneizi
\n
Turnstone Biologics
\n
(347) 897-5988
\n
ahmed.aneizi@turnstonebio.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Presentations demonstrate therapeutic potential of Turnstone\u2019s selected tumor-infiltrating lymphocyte therapy in a broad range of solid tumors and support ongoing clinical efforts for its lead program, TIDAL-01 SAN DIEGO–(BUSINESS WIRE)–#AACR2023–Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation immunotherapies to treat solid tumors, today announced that two abstracts have been accepted for poster presentations at … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55772","6":"format-standard","7":"category-industry"},"yoast_head":"\nTurnstone Biologics to Present Preclinical Data for Selected TIL Therapy at the 2023 American Association for Cancer Research (AACR) Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Turnstone Biologics to Present Preclinical Data for Selected TIL Therapy at the 2023 American Association for Cancer Research (AACR) Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Presentations demonstrate therapeutic potential of Turnstone\u2019s selected tumor-infiltrating lymphocyte therapy in a broad range of solid tumors and support ongoing clinical efforts for its lead program, TIDAL-01 SAN DIEGO–(BUSINESS WIRE)–#AACR2023–Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation immunotherapies to treat solid tumors, today announced that two abstracts have been accepted for poster presentations at ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-13T10:05:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230413005350\/en\/1762900\/21\/TSTN_Logo_Twitter.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Turnstone Biologics to Present Preclinical Data for Selected TIL Therapy at the 2023 American Association for Cancer Research (AACR) Annual Meeting\",\"datePublished\":\"2023-04-13T10:05:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/\"},\"wordCount\":557,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230413005350\\\/en\\\/1762900\\\/21\\\/TSTN_Logo_Twitter.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/\",\"name\":\"Turnstone Biologics to Present Preclinical Data for Selected TIL Therapy at the 2023 American Association for Cancer Research (AACR) Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230413005350\\\/en\\\/1762900\\\/21\\\/TSTN_Logo_Twitter.jpg\",\"datePublished\":\"2023-04-13T10:05:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230413005350\\\/en\\\/1762900\\\/21\\\/TSTN_Logo_Twitter.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230413005350\\\/en\\\/1762900\\\/21\\\/TSTN_Logo_Twitter.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Turnstone Biologics to Present Preclinical Data for Selected TIL Therapy at the 2023 American Association for Cancer Research (AACR) Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Turnstone Biologics to Present Preclinical Data for Selected TIL Therapy at the 2023 American Association for Cancer Research (AACR) Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Turnstone Biologics to Present Preclinical Data for Selected TIL Therapy at the 2023 American Association for Cancer Research (AACR) Annual Meeting - Pharma Trend","og_description":"Presentations demonstrate therapeutic potential of Turnstone\u2019s selected tumor-infiltrating lymphocyte therapy in a broad range of solid tumors and support ongoing clinical efforts for its lead program, TIDAL-01 SAN DIEGO–(BUSINESS WIRE)–#AACR2023–Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation immunotherapies to treat solid tumors, today announced that two abstracts have been accepted for poster presentations at ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-13T10:05:41+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230413005350\/en\/1762900\/21\/TSTN_Logo_Twitter.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Turnstone Biologics to Present Preclinical Data for Selected TIL Therapy at the 2023 American Association for Cancer Research (AACR) Annual Meeting","datePublished":"2023-04-13T10:05:41+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/"},"wordCount":557,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230413005350\/en\/1762900\/21\/TSTN_Logo_Twitter.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/","name":"Turnstone Biologics to Present Preclinical Data for Selected TIL Therapy at the 2023 American Association for Cancer Research (AACR) Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230413005350\/en\/1762900\/21\/TSTN_Logo_Twitter.jpg","datePublished":"2023-04-13T10:05:41+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230413005350\/en\/1762900\/21\/TSTN_Logo_Twitter.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230413005350\/en\/1762900\/21\/TSTN_Logo_Twitter.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/turnstone-biologics-to-present-preclinical-data-for-selected-til-therapy-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Turnstone Biologics to Present Preclinical Data for Selected TIL Therapy at the 2023 American Association for Cancer Research (AACR) Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55772"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55772\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55772"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55772"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}